Charles River Laboratories International (CRL) Competitors

$221.61
-3.14 (-1.40%)
(As of 05/17/2024 ET)

CRL vs. MEDP, INCY, ICLR, IQV, DVA, UTHR, UHS, PODD, RDY, and SWAV

Should you be buying Charles River Laboratories International stock or one of its competitors? The main competitors of Charles River Laboratories International include Medpace (MEDP), Incyte (INCY), ICON Public (ICLR), IQVIA (IQV), DaVita (DVA), United Therapeutics (UTHR), Universal Health Services (UHS), Insulet (PODD), Dr. Reddy's Laboratories (RDY), and Shockwave Medical (SWAV). These companies are all part of the "medical" sector.

Charles River Laboratories International vs.

Charles River Laboratories International (NYSE:CRL) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.

Charles River Laboratories International has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Charles River Laboratories International received 145 more outperform votes than Medpace when rated by MarketBeat users. However, 64.00% of users gave Medpace an outperform vote while only 61.59% of users gave Charles River Laboratories International an outperform vote.

CompanyUnderperformOutperform
Charles River Laboratories InternationalOutperform Votes
481
61.59%
Underperform Votes
300
38.41%
MedpaceOutperform Votes
336
64.00%
Underperform Votes
189
36.00%

Medpace has a net margin of 15.92% compared to Charles River Laboratories International's net margin of 10.81%. Medpace's return on equity of 59.74% beat Charles River Laboratories International's return on equity.

Company Net Margins Return on Equity Return on Assets
Charles River Laboratories International10.81% 15.16% 6.60%
Medpace 15.92%59.74%19.70%

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Medpace had 3 more articles in the media than Charles River Laboratories International. MarketBeat recorded 22 mentions for Medpace and 19 mentions for Charles River Laboratories International. Medpace's average media sentiment score of 1.02 beat Charles River Laboratories International's score of 0.70 indicating that Medpace is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Charles River Laboratories International
6 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
8 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Charles River Laboratories International presently has a consensus target price of $255.27, indicating a potential upside of 15.19%. Medpace has a consensus target price of $443.00, indicating a potential upside of 12.64%. Given Charles River Laboratories International's higher possible upside, research analysts plainly believe Charles River Laboratories International is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Charles River Laboratories International
0 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.64
Medpace
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Charles River Laboratories International has higher revenue and earnings than Medpace. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$4.13B2.76$474.62M$8.5026.07
Medpace$1.89B6.46$282.81M$9.8140.09

Summary

Medpace beats Charles River Laboratories International on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRL vs. The Competition

MetricCharles River Laboratories InternationalCommercial physical research IndustryMedical SectorNYSE Exchange
Market Cap$11.42B$5.39B$5.11B$18.05B
Dividend YieldN/A1.11%43.85%3.43%
P/E Ratio26.0722.37148.0023.97
Price / Sales2.7675.742,361.3710.29
Price / Cash13.8426.1636.6420.14
Price / Book3.133.845.766.01
Net Income$474.62M$136.66M$104.93M$966.25M
7 Day Performance-2.85%-2.10%1.87%1.87%
1 Month Performance-2.61%-9.72%4.76%7.16%
1 Year Performance11.22%-1.08%7.73%21.68%

Charles River Laboratories International Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MEDP
Medpace
4.9176 of 5 stars
$398.52
+2.4%
$443.00
+11.2%
+88.0%$12.35B$1.96B40.625,900Analyst Revision
Positive News
INCY
Incyte
4.8597 of 5 stars
$57.05
-1.0%
$74.93
+31.3%
-11.5%$12.93B$3.77B17.292,524Short Interest ↑
ICLR
ICON Public
2.7819 of 5 stars
$315.57
+2.0%
$339.44
+7.6%
+49.4%$26.03B$8.12B38.3941,100
IQV
IQVIA
4.7478 of 5 stars
$231.14
+0.9%
$257.57
+11.4%
+19.8%$42.11B$14.98B31.5887,000
DVA
DaVita
3.792 of 5 stars
$137.01
+0.3%
$129.75
-5.3%
+41.8%$12.02B$12.14B15.5770,000Analyst Forecast
Insider Selling
UTHR
United Therapeutics
4.8964 of 5 stars
$269.78
+2.1%
$308.78
+14.5%
+26.9%$11.97B$2.33B12.761,168Analyst Upgrade
Insider Selling
UHS
Universal Health Services
4.9119 of 5 stars
$178.91
+0.2%
$183.20
+2.4%
+32.2%$12.03B$14.28B15.1696,700Dividend Announcement
PODD
Insulet
4.9445 of 5 stars
$172.27
+7.0%
$239.44
+39.0%
-40.2%$12.06B$1.70B52.203,000Gap Up
High Trading Volume
RDY
Dr. Reddy's Laboratories
0.7589 of 5 stars
$69.68
-0.3%
$81.00
+16.2%
+25.0%$11.63B$3.35B17.2925,863Analyst Downgrade
SWAV
Shockwave Medical
4.4435 of 5 stars
$331.00
+0.2%
$309.11
-6.6%
+19.3%$12.43B$730.23M77.341,468Positive News

Related Companies and Tools

This page (NYSE:CRL) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners